Celecoxib

Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the nonsteroidal anti-inflammatory drug (NSAID) class, distinguished by its preferential blockade of the inducible COX-2 isoform over the constitutively expressed COX-1. By inhibiting COX-2, celecoxib suppresses the enzymatic conversion of arachidonic acid to prostaglandin H2, thereby reducing downstream synthesis of prostaglandin E2 (PGE2) and other pro-inflammatory eicosanoids. This mechanism underlies its well-established clinical use in managing pain, osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Compared to non-selective NSAIDs such as (RS)-ketoprofen or sulindac, celecoxib's COX-2 selectivity is associated with a reduced risk of gastrointestinal ulceration, making it a widely used reference compound in anti-inflammatory research. In preclinical and translational settings, its inhibition of the COX-2/PGE2 axis also positions it as a candidate for modulating neuroinflammation, cancer-related inflammation, and chemotherapy-induced adverse effects.

Beyond its canonical anti-inflammatory role, celecoxib has attracted growing interest as an oncological adjunct and a neurological therapeutic. Its ability to suppress proinflammatory cytokine signaling — including pathways involving TNF-α and Interleukin-6 (IL-6) — and to downregulate Cyclooxygenase 2 (COX-2) (PTGS2/COX-2) expression at the transcriptional level has prompted investigation into its utility across a remarkably broad spectrum of diseases. The drug's well-characterized pharmacology and decades of clinical safety data make it a frequent positive control and benchmark comparator in studies evaluating novel anti-inflammatory and antitumor agents.